<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>COSOPT PF- dorzolamide hydrochloride and timolol maleate solution/ drops </strong><br>Akorn, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use COSOPT PF safely and effectively. See full prescribing information for COSOPT PF.<br>COSOPT® PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%/0.5% <br>Initial U.S. Approval: 1998
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul class="Disc">
<li>COSOPT PF is a carbonic anhydrase inhibitor with a beta-adrenergic receptor blocking agent indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> who are insufficiently responsive to beta-blockers.
</li>
<li>The IOP-lowering of COSOPT twice daily was slightly less than that seen with the concomitant administration of 0.5% timolol twice daily, and 2% dorzolamide three times daily. (<a href="#s1">1</a>)
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">The dose is one drop of COSOPT PF in the affected eye(s) two times daily. (<a href="#s2">2</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Solution containing 20 mg/mL dorzolamide and 5 mg/mL timolol. (<a href="#s3">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta">COSOPT PF is contraindicated in patients with:
 </p>
<ul class="Disc">
<li>Bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>. (<a href="#s5">4.1</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span>, second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>. (<a href="#s6">4.2</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product. (<a href="#s7">4.3</a>, <a href="#s11">5.3</a>)
</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Potentiation of Respiratory Reactions Including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> (<a href="#s9">5.1</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span> (<a href="#s10">5.2</a>)
</li>
<li>Sulfonamide <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<a href="#s11">5.3</a>)
</li>
<li>Obstructive Pulmonary Disease (<a href="#s12">5.4</a>)
</li>
<li>Increased Reactivity to Allergens (<a href="#s13">5.5</a>)
</li>
<li>Potentiation of <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span> (<a href="#s14">5.6</a>)
</li>
<li>Masking of Hypoglycemic Symptoms in Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus (<a href="#s15">5.7</a>)
</li>
<li>Masking of <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span> (<a href="#s16">5.8</a>)
</li>
<li>Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (<a href="#s17">5.9</a>)
</li>
<li>Impairment of Beta-Adrenergically Mediated Reflexes During Surgery (<a href="#s18">5.10</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most frequently reported adverse reactions were <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span> (bitter, sour, or unusual taste) or ocular burning and/or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> in up to 30% of patients. <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">Conjunctival hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="375265" conceptname="Punctate keratitis">superficial punctate keratitis</span> or <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye itching</span> were reported between 5-15% of patients. (<a href="#s20">6</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Akorn at 1-800-932-5676 or FDA at 1-800-FDA-1088 or </span><span class="Bold Underline">www.fda.gov/medwatch</span><span class="Bold">.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Potential additive effect of oral carbonic anhydrase inhibitor with COSOPT PF. (<a href="#s28">7.1</a>)
</li>
<li>Potential acid-base and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>. (<a href="#s29">7.2</a>)
</li>
<li>Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade. (<a href="#s30">7.3</a>)
</li>
<li>Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. (<a href="#s31">7.4</a>)
</li>
<li>Catecholamine-depleting drugs may have additive effects and produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. (<a href="#s32">7.5</a>)
</li>
<li>Digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time. (<a href="#s33">7.6</a>)
</li>
<li>CYP2D6 inhibitors may potentiate systemic beta-blockade. (<a href="#s34">7.7</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 12/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>
</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV Block</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">Cardiogenic Shock</span>
</a></h2>
<h2><a href="#section-4.3" class="toc">4.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Potentiation of Respiratory Reactions Including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Sulfonamide <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Obstructive Pulmonary Disease
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Increased Reactivity to Allergens
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Potentiation of <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span>
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Masking of Hypoglycemic Symptoms in Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Masking of <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span>
</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Impairment of Beta-Adrenergically Mediated Reflexes During Surgery
</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Corneal Endothelium
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Oral Carbonic Anhydrase Inhibitors
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 High-Dose Salicylate Therapy
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Beta-Adrenergic Blocking Agents
</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Calcium Antagonists
</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Catecholamine-Depleting Drugs
</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Digitalis and Calcium Antagonists
</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 CYP2D6 Inhibitors
</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Clonidine
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 COSOPT Efficacy
</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 COSOPT PF Equivalence Study
</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Potential for <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">Exacerbation of Asthma</span> and <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>
</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Potential of Cardiovascular Effects
</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Sulfonamide Reactions
</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Handling the Single-Use Container
</a></h2>
<h2><a href="#section-15.5" class="toc">17.5 Intercurrent Ocular Conditions
</a></h2>
<h2><a href="#section-15.6" class="toc">17.6 Concomitant Topical Ocular Therapy
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First">COSOPT® PF is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT® administered twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol administered twice a day and 2% dorzolamide administered three times a day <span class="Italics">[see Clinical Studies (<a href="#s51">14.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First">The dose is one drop of COSOPT PF in the affected eye(s) two times daily.
</p>
<p>If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart <span class="Italics">[see Drug Interactions (<a href="#s30">7.3</a>)].</span></p>
<p>The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> cannot be maintained after the individual unit is opened, the remaining contents should be discarded immediately after administration.
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Solution containing 20 mg/mL dorzolamide (22.26 mg of dorzolamide hydrochloride) and 5 mg/mL timolol (6.83 mg timolol maleate).
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>
</h2>
<p class="First">COSOPT PF is contraindicated in patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, or severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> <span class="Italics">[see Warnings and Precautions (<a href="#s9">5.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-4.2"></a><p></p>
<h2>4.2 <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV Block</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">Cardiogenic Shock</span>
</h2>
<p class="First">COSOPT PF is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, and <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span> <span class="Italics">[see Warnings and Precautions (<a href="#s10">5.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-4.3"></a><p></p>
<h2>4.3 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</h2>
<p class="First">COSOPT PF is contraindicated in patients who are hypersensitive to any component of this product <span class="Italics">[see Warnings and Precautions (<a href="#s11">5.3</a>)]</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Potentiation of Respiratory Reactions Including <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>
</h2>
<p class="First">COSOPT PF contains timolol maleate, a beta-adrenergic blocking agent; and although administered topically, is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and rarely <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in association with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, have been reported following systemic or ophthalmic administration of timolol maleate <span class="Italics">[see Contraindications (<a href="#s5">4.1</a>) and Patient Counseling Information (<a href="#s55">17.1</a>)]</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>
</h2>
<p class="First">Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.
</p>
<p>In patients without a history of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, COSOPT PF should be discontinued <span class="Italics">[see Contraindications (<a href="#s6">4.2</a>) and Patient Counseling Information (<a href="#s56">17.2</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Sulfonamide <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>
</h2>
<p class="First">COSOPT PF contains dorzolamide, a sulfonamide; and although administered topically, it is absorbed systemically. Therefore, the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration of COSOPT PF. Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and other <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasias</span>. Sensitization may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of serious reactions or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> occur, discontinue the use of this preparation <span class="Italics">[see Contraindications (<a href="#s7">4.3</a>) and Patient Counseling Information (<a href="#s57">17.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Obstructive Pulmonary Disease
</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, in which COSOPT PF is contraindicated) should, in general, not receive beta-blocking agents, including COSOPT PF <span class="Italics">[see Contraindications (<a href="#s5">4.1</a>) and Patient Counseling Information (<a href="#s55">17.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Increased Reactivity to Allergens
</h2>
<p class="First">While taking beta-blockers, patients with a history of <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopy</span> or a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Potentiation of <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span>
</h2>
<p class="First">Beta-adrenergic blockade has been reported to potentiate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> consistent with certain myasthenic symptoms (e.g., <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>). Timolol has been reported rarely to increase <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in some patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or myasthenic symptoms.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Masking of Hypoglycemic Symptoms in Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus
</h2>
<p class="First">Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or to diabetic patients (especially those with labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Masking of <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span>
</h2>
<p class="First">Beta-adrenergic blocking agents may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">Dorzolamide has not been studied in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl &lt;30 mL/min). Because dorzolamide and its metabolite are excreted predominantly by the kidney, COSOPT PF is not recommended in such patients.
</p>
<p>Dorzolamide has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and should therefore be used with caution in such patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Impairment of Beta-Adrenergically Mediated Reflexes During Surgery
</h2>
<p class="First">The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents.
</p>
<p>If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Corneal Endothelium
</h2>
<p class="First">Carbonic anhydrase activity has been observed in both the cytoplasm and around the plasma membranes of the corneal endothelium. There is an increased potential for developing <span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">corneal edema</span> in patients with low endothelial cell counts. Caution should be used when prescribing COSOPT PF to this group of patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s20"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">COSOPT and COSOPT PF</span></p>
<p>COSOPT and COSOPT PF were evaluated in patients with elevated intraocular pressure treated for open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> for up to 15 months. Approximately 5% of all patients discontinued therapy because of adverse reactions.
</p>
<p>The most frequently reported adverse reactions occurring in up to 30% of patients were <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span> (bitter, sour, or unusual taste) or ocular burning and/or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>. The following adverse reactions were reported in 5-15% of patients: <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="375265" conceptname="Punctate keratitis">superficial punctate keratitis</span> or <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">eye itching</span>.
</p>
<p>The following adverse reactions were reported in 1-5% of patients: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">cloudy vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctival discharge</span>, <span class="product-label-link" type="condition" conceptid="380117" conceptname="Conjunctival edema">conjunctival edema</span>, <span class="product-label-link" type="condition" conceptid="4224417" conceptname="Conjunctival follicle">conjunctival follicles</span>, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival injection</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="4080997" conceptname="Corneal epithelial staining pattern">corneal staining</span>, cortical <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">lens opacity</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dryness of eyes</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, eye debris, <span class="product-label-link" type="condition" conceptid="4080696" conceptname="Discharge from eye">eye discharge</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, eye tearing, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>, eyelid <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, eyelid exudate/scales, eyelid <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, foreign body sensation, glaucomatous cupping, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, lens nucleus coloration, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">lens opacity</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, nuclear <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">lens opacity</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, post-<span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">subcapsular cataract</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>, <span class="product-label-link" type="condition" conceptid="4202518" conceptname="Vitreous detachment">vitreous detachment</span>.
</p>
<p>Other adverse reactions that have been reported with the individual components are listed below:
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Dorzolamide 2%</span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, eyelid crusting, <span class="product-label-link" type="condition" conceptid="372912" conceptname="Visual discomfort">ocular discomfort</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, signs and symptoms of ocular <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold">Timolol (ocular administration)</span></p>
<p><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; <span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, worsening of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">claudication</span>, Raynaud's phenomenon, and <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">cold hands</span> and feet; <span class="Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>; <span class="Italics">Immunologic:</span> <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic lupus erythematosus</span>; <span class="Italics">Nervous System/Psychiatric:</span> Increase in signs and symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, behavioral changes and <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span> including <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>; <span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, psoriasiform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">exacerbation of psoriasis</span>; <span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and localized and generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (predominantly in patients with pre-existing bronchospastic disease); <span class="Italics">Endocrine:</span> Masked symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in diabetic patients; <span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">Ptosis</span>, decreased corneal sensitivity, <span class="product-label-link" type="condition" conceptid="4105178" conceptname="Cystoid macular edema">cystoid macular edema</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> including refractive changes and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, pseudopemphigoid, and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>; <span class="Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">Retroperitoneal fibrosis</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, and Peyronie's disease.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience
</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of COSOPT or COSOPT PF. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">choroidal detachment</span> following filtration surgery, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">iridocyclitis</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="product-label-link" type="condition" conceptid="79873" conceptname="Urolith">urolithiasis</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Bold">Timolol (oral administration)</span></p>
<p>The following additional adverse reactions have been reported in clinical experience with ORAL timolol maleate or other ORAL beta-blocking agents and may be considered potential effects of ophthalmic timolol maleate: <span class="Italics">Allergic:</span> Erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> with <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>; <span class="Italics">Body as a Whole:</span> Extremity <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, decreased exercise tolerance, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>; <span class="Italics">Cardiovascular:</span> Worsening of <span class="product-label-link" type="condition" conceptid="4109870" conceptname="Arterial insufficiency">arterial insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>; <span class="Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">Gastrointestinal pain</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>; <span class="Italics">Hematologic:</span> Nonthrombocytopenic <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>; <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; <span class="Italics">Endocrine:</span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>; <span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; <span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>; <span class="Italics">Nervous System/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, local <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, diminished concentration, reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>, an acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, slightly clouded sensorium, and decreased performance on neuropsychometrics; <span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span>, <span class="product-label-link" type="condition" conceptid="4279071" conceptname="Obstruction of bronchus">bronchial obstruction</span>; <span class="Italics">Urogenital:</span> Urination difficulties.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s27"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Oral Carbonic Anhydrase Inhibitors
</h2>
<p class="First">There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients receiving an oral carbonic anhydrase inhibitor and COSOPT PF. The concomitant administration of COSOPT PF and oral carbonic anhydrase inhibitors is not recommended.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-7.2"></a><p></p>
<h2>7.2 High-Dose Salicylate Therapy
</h2>
<p class="First">Although acid-base and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span> were not reported in the clinical trials with dorzolamide hydrochloride ophthalmic solution, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy). Therefore, the potential for such drug interactions should be considered in patients receiving COSOPT PF.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Beta-Adrenergic Blocking Agents
</h2>
<p class="First">Patients who are receiving a beta-adrenergic blocking agent orally and COSOPT PF should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Calcium Antagonists
</h2>
<p class="First">Caution should be used in the coadministration of beta-adrenergic blocking agents, such as COSOPT PF, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In patients with impaired cardiac function, coadministration should be avoided.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Catecholamine-Depleting Drugs
</h2>
<p class="First">Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, which may result in <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Digitalis and Calcium Antagonists
</h2>
<p class="First">The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-7.7"></a><p></p>
<h2>7.7 CYP2D6 Inhibitors
</h2>
<p class="First">Potentiated systemic beta-blockade (e.g., decreased heart rate, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-7.8"></a><p></p>
<h2>7.8 Clonidine
</h2>
<p class="First">Oral beta-adrenergic blocking agents may exacerbate the <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> which can follow the withdrawal of clonidine. There have been no reports of exacerbation of <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> with ophthalmic timolol maleate.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s36"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s37"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s38"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics">Teratogenic Effects</span>. Pregnancy Category C. Developmental toxicity studies with dorzolamide hydrochloride in rabbits at oral doses of ≥2.5 mg/kg/day (31 times the recommended human ophthalmic dose) revealed malformations of the vertebral bodies. These malformations occurred at doses that caused <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> with decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in dams and decreased fetal weights. No treatment-related malformations were seen at 1 mg/kg/day (13 times the recommended human ophthalmic dose).
</p>
<p><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.
</p>
<p>There are no adequate and well-controlled studies in pregnant women. COSOPT PF should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s39"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">It is not known whether dorzolamide is excreted in human milk. Timolol maleate has been detected in human milk following oral and ophthalmic drug administration. Because of the potential for serious adverse reactions from COSOPT PF in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s40"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">The safety and effectiveness of dorzolamide hydrochloride ophthalmic solution and timolol maleate ophthalmic solution have been established when administered individually in pediatric patients aged 2 years and older. Use of these drug products in these children is supported by evidence from adequate and well-controlled studies in children and adults. Safety and efficacy in pediatric patients below the age of 2 years have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s41"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s42"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First">Symptoms consistent with systemic administration of beta-blockers or carbonic anhydrase inhibitors may occur, including <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, development of an acidotic state, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and possible central nervous system effects. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored. <span class="Italics">[See Adverse Reactions (<a href="#s20">6</a>).]</span></p>
<p>A study of patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> showed that timolol did not dialyze readily.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s43"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">COSOPT PF (dorzolamide hydrochloride-timolol maleate ophthalmic solution) is the combination of a topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent.
</p>
<p>Dorzolamide hydrochloride is described chemically as: (4<span class="Italics">S-trans</span>)-4-(ethylamino)-5,6-dihydro-6-methyl-4<span class="Italics">H</span>-thieno[2,3-<span class="Italics">b</span>]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride. Dorzolamide hydrochloride is optically active. The specific rotation is:
</p>
<dl>
<dt> 
</dt>
<dd>[α]        25°C        (C=1, water) = ~ -17°.
</dd>
<dt> 
</dt>
<dd>             405 nm
</dd>
</dl>
<p>Its empirical formula is C<span class="Sub">10</span>H<span class="Sub">16</span>N<span class="Sub">2</span>O<span class="Sub">4</span>S<span class="Sub">3</span>•HCl and its structural formula is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e&amp;name=cos03-0000-01.jpg">
</div>
<p>Dorzolamide hydrochloride has a molecular weight of 360.91. It is a white to off-white, crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol.
</p>
<p>Timolol maleate is described chemically as: (-)-1-(<span class="Italics">tert</span>-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:
</p>
<dl>
<dt> 
</dt>
<dd>[α]        25°C       in 1N HCl (C = 5) = -12.2° (-11.7° to -12.5°).
</dd>
<dt> 
</dt>
<dd>             405 nm
</dd>
</dl>
<p>Its molecular formula is C<span class="Sub">13</span>H<span class="Sub">24</span>N<span class="Sub">4</span>O<span class="Sub">3</span>S•C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span> and its structural formula is:
</p>
<div class="Figure">
<a name="f02"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e&amp;name=cos03-0000-02.jpg">
</div>
<p>Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.
</p>
<p>COSOPT PF is supplied as a sterile, clear, colorless to nearly colorless, isotonic, buffered, slightly viscous, aqueous solution. The pH of the solution is approximately 5.65, and the osmolarity is 242-323 mOsM. Each mL of COSOPT PF contains 20 mg dorzolamide (22.26 mg of dorzolamide hydrochloride) and 5 mg timolol (6.83 mg timolol maleate). Inactive ingredients are sodium citrate, hydroxyethyl cellulose, sodium hydroxide, mannitol, and water for injection.
</p>
<p>COSOPT PF does not contain a preservative.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s44"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s45"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">COSOPT PF is comprised of two components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure, whether or not associated with <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, by reducing aqueous humor secretion. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span> and glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous field loss and optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>.
</p>
<p>Dorzolamide hydrochloride is an inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> ions with subsequent reduction in sodium and fluid transport. Timolol maleate is a beta<span class="Sub">1</span> and beta<span class="Sub">2</span> (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. The combined effect of these two agents administered as COSOPT PF administered twice daily results in additional intraocular pressure reduction compared to either component administered alone, but the reduction is not as much as when dorzolamide administered three times daily and timolol twice daily are administered concomitantly. <span class="Italics">[See Clinical Studies (<a href="#s50">14</a>).]</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s46"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Dorzolamide Hydrochloride</span></p>
<p>When topically applied, dorzolamide reaches the systemic circulation. To assess the potential for systemic carbonic anhydrase inhibition following topical administration, drug and metabolite concentrations in RBCs and plasma and carbonic anhydrase inhibition in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of binding to CA-II. The parent drug forms a single N-desethyl metabolite, which inhibits CA-II less potently than the parent drug but also inhibits CA-I. The metabolite also accumulates in RBCs where it binds primarily to CA-I. Plasma concentrations of dorzolamide and metabolite are generally below the assay limit of quantitation (15nM). Dorzolamide binds moderately to plasma proteins (approximately 33%).
</p>
<p>Dorzolamide is primarily excreted unchanged in the urine; the metabolite also is excreted in urine. After dosing is stopped, dorzolamide washes out of RBCs nonlinearly, resulting in a rapid decline of drug concentration initially, followed by a slower elimination phase with a half-life of about four months.
</p>
<p>To simulate the systemic exposure after long-term topical ocular administration, dorzolamide was given orally to eight healthy subjects for up to 20 weeks. The oral dose of 2 mg twice daily closely approximates the amount of drug delivered by topical ocular administration of dorzolamide 2% three times daily. Steady state was reached within 8 weeks. The inhibition of CA-II and total carbonic anhydrase activities was below the degree of inhibition anticipated to be necessary for a pharmacological effect on renal function and respiration in healthy individuals. 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e46"></a><a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Italics">Timolol Maleate</span></p>
<p>In a study of plasma drug concentrations in six subjects, the systemic exposure to timolol was determined following twice daily topical administration of timolol maleate ophthalmic solution 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s48"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s49"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">In a two-year study of dorzolamide hydrochloride administered orally to male and female Sprague-Dawley rats, urinary bladder <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> were seen in male rats in the highest dosage group of 20 mg/kg/day (250 times the recommended human ophthalmic dose). <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">Papillomas</span> were not seen in rats given oral doses equivalent to approximately 12 times the recommended human ophthalmic dose. No treatment-related tumors were seen in a 21-month study in female and male mice given oral doses up to 75 mg/kg/day (~900 times the recommended human ophthalmic dose).
</p>
<p>The increased incidence of urinary bladder <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> seen in the high-dose male rats is a class-effect of carbonic anhydrase inhibitors in rats. Rats are particularly prone to developing <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papillomas</span> in response to foreign bodies, compounds causing <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>, and diverse sodium salts.
</p>
<p>No changes in bladder urothelium were seen in dogs given oral dorzolamide hydrochloride for one year at 2 mg/kg/day (25 times the recommended human ophthalmic dose) or monkeys dosed topically to the eye at 0.4 mg/kg/day (~5 times the recommended human ophthalmic dose) for one year.
</p>
<p>In a two-year study of timolol maleate administered orally to rats, there was a statistically significant increase in the incidence of adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> in male rats administered 300 mg/kg/day (approximately 42,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Similar differences were not observed in rats administered oral doses equivalent to approximately 14,000 times the maximum recommended human ophthalmic dose.
</p>
<p>In a lifetime oral study of timolol maleate in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumors, benign uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> and mammary adenocarcinomas in female mice at 500 mg/kg/day, (approximately 71,000 times the systemic exposure following the maximum recommended human ophthalmic dose), but not at 5 or 50 mg/kg/day (approximately 700 or 7,000, respectively, times the systemic exposure following the maximum recommended human ophthalmic dose). In a subsequent study in female mice, in which post-mortem examinations were limited to the uterus and the lungs, a statistically significant increase in the incidence of pulmonary tumors was again observed at 500 mg/kg/day.
</p>
<p>The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin which occurred in female mice administered oral timolol at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumors has been established in humans. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate (the maximum recommended human oral dosage), there were no clinically meaningful changes in serum prolactin.
</p>
<p>The following tests for mutagenic potential were negative for dorzolamide: (1) <span class="Italics">in vivo</span> (mouse) cytogenetic assay; (2) <span class="Italics">in vitro</span> chromosomal aberration assay; (3) alkaline elution assay; (4) V-79 assay; and (5) Ames test.
</p>
<p>Timolol maleate was devoid of mutagenic potential when tested <span class="Italics">in vivo</span> (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and <span class="Italics">in vitro</span> in a neoplastic cell transformation assay (up to 100 μg/mL). In Ames tests the highest concentrations of timolol employed, 5,000 or 10,000 μg/plate, were associated with statistically significant elevations of revertants observed with tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100 (in seven replicate assays), but not in the remaining three <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. In the assays with tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100, no consistent dose response relationship was observed, and the ratio of test to control revertants did not reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test.
</p>
<p>Reproduction and fertility studies in rats with either timolol maleate or dorzolamide hydrochloride demonstrated no adverse effect on male or female fertility at doses up to approximately 100 times the systemic exposure following the maximum recommended human ophthalmic dose.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s50"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-13.1"></a><p></p>
<h2>14.1 COSOPT Efficacy
</h2>
<p class="First">Clinical studies of 3 to 15 months duration were conducted to compare the IOP-lowering effect over the course of the day of COSOPT twice daily (dosed morning and bedtime) to individually- and concomitantly-administered 0.5% timolol twice daily and 2.0% dorzolamide twice and three times daily. The IOP-lowering effect of COSOPT twice daily was greater (1-3 mmHg) than that of monotherapy with either 2.0% dorzolamide three times daily or 0.5% timolol twice daily. The IOP-lowering effect of COSOPT twice daily was approximately 1 mmHg less than that of concomitant therapy with 2.0% dorzolamide three times daily and 0.5% timolol twice daily.
</p>
<p>Open-label extensions of two studies were conducted for up to 12 months. During this period, the IOP-lowering effect of COSOPT twice daily was consistent during the 12 month follow-up period.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-13.2"></a><p></p>
<h2>14.2 COSOPT PF Equivalence Study
</h2>
<p class="First">In an active-treatment controlled, parallel, double-masked study in 261 patients with elevated intraocular pressure ≥22 mmHg in one or both eyes, COSOPT PF had an IOP-lowering effect equivalent to that of COSOPT.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s53"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">COSOPT PF is supplied in a foil pouch containing 15 low density polyethylene 0.2 mL single-use containers.
</p>
<p><span class="Bold">NDC</span> 17478-604-30, package of 60 single-use vials.
</p>
<p><span class="Bold">NDC</span> 17478-604-90, package of 180 single-use vials.
</p>
<p>Store COSOPT PF at 20° to 25°C (68° to 77°F). Do not freeze.
</p>
<p>Store in the original pouch. After the pouch is opened, store the remaining single-use containers in the foil pouch to protect from light. Write down the date you open the foil pouch in the space provided on the pouch. Discard any unused containers 15 days after first opening the pouch.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s54"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">See FDA-Approved Patient Labeling (<a href="#s61">Patient Information</a>).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Potential for <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">Exacerbation of Asthma</span> and <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>
</h2>
<p class="First">COSOPT PF may cause severe worsening of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> symptoms including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. Patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> should be advised not to take this product. <span class="Italics">[See Contraindications (<a href="#s5">4.1</a>).]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Potential of Cardiovascular Effects
</h2>
<p class="First">COSOPT PF may cause worsening of cardiac symptoms. Patients with <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> should be advised not to take this product. <span class="Italics">[See Contraindications (<a href="#s6">4.2</a>).]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Sulfonamide Reactions
</h2>
<p class="First">COSOPT PF contains dorzolamide (which is a sulfonamide) and, although administered topically, is absorbed systemically. Therefore the same types of adverse reactions that are attributable to sulfonamides may occur with topical administration, including severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. Patients should be advised that if serious or unusual reactions or signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> occur, they should discontinue the use of the product and seek their physician's advice. <span class="Italics">[See Warnings and Precautions (<a href="#s11">5.3</a>).]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Handling the Single-Use Container
</h2>
<p class="First">COSOPT PF is a sterile solution that does not contain a preservative. The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> cannot be maintained after the individual unit is opened, the remaining contents should be discarded immediately after administration.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-15.5"></a><p></p>
<h2>17.5 Intercurrent Ocular Conditions
</h2>
<p class="First">Patients also should be advised that if they have ocular surgery or develop an intercurrent ocular condition (e.g., <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>), they should immediately seek their physician's advice concerning the continued use of this product.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-15.6"></a><p></p>
<h2>17.6 Concomitant Topical Ocular Therapy
</h2>
<p class="First">If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.
</p>
<p><span class="Bold">AKORN<br></span>Distributed by: Akorn, Inc.<br>Lake Forest, IL 60045
</p>
<p>The COSOPT trademark is owned by Merck Sharp &amp; Dohme Corp. and is used under license.
</p>
<p>PF00N      Revision 12/2013
</p>
<p>AK60300
</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="s61"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">COSOPT</span><span class="Bold"><span class="Sup">®
</span></span><span class="Bold">PF (CO-sopt PEA EHF)</span></p>
<p><span class="Bold">(dorzolamide hydrochloride-timolol maleate ophthalmic solution) 2%/0.5%</span></p>
<p>Read this information before you start using COSOPT PF and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.
</p>
<p><span class="Bold">What is COSOPT PF?</span></p>
<p>COSOPT PF is a prescription sterile eye drop solution that contains 2 medicines, dorzolamide hydrochloride (a sulfonamide carbonic anhydrase inhibitor) and timolol maleate (a beta-adrenergic blocker). COSOPT PF is used to lower the pressure in the eye (intraocular pressure) in people with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span>, when their eye pressure is too high and beta-adrenergic blocker medicines alone have not adequately lowered the pressure.
</p>
<p>It is not known if COSOPT PF is safe and effective in children under 2 years of age.
</p>
<p><span class="Bold">Who should not use COSOPT PF?</span></p>
<p>Do not use COSOPT PF if you:
</p>
<ul class="Disc">
<li>have or have had <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>
</li>
<li>have or have had severe lung problems (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>)
</li>
<li>have heart problems, including slow or irregular heartbeat or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>
</li>
<li>are allergic to dorzolamide hydrochloride, timolol maleate, or any of the ingredients in COSOPT PF. See the end of this leaflet for a complete list of ingredients in COSOPT PF.
</li>
</ul>
<p>Talk to your healthcare provider before taking this medicine if you have any of these conditions.
</p>
<p><span class="Bold">What should I tell my doctor before using COSOPT PF?</span></p>
<p><span class="Bold">Before you use COSOPT PF, tell your doctor if you:</span></p>
<ul class="Disc">
<li>have problems with <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> (<span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>)
</li>
<li>have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or problems with low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>)
</li>
<li>have thyroid, kidney, or liver problems
</li>
<li>are planning to have surgery
</li>
<li>are allergic to sulfa drugs
</li>
<li>have or have had eye problems, including any surgery on your eye or eyes, or are using any other eye medicines
</li>
<li>have any other medical problems
</li>
<li>are pregnant or plan to become pregnant. It is not known if COSOPT PF will harm your unborn baby. If you become pregnant while using COSOPT PF talk to your doctor right away.
</li>
<li>are breastfeeding or plan to breastfeed. It is not known whether dorzolamide passes into your breast milk however, timolol has been detected in breast milk. Talk to your doctor about the best way to feed your baby if you use COSOPT PF.
</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take</span>, including prescription and non-prescription medicines, vitamins, and herbal supplements.
</p>
<p>COSOPT PF and other medicines may affect each other causing side effects. COSOPT PF may affect the way other medicines work, and other medicines may affect how COSOPT PF works.
</p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
</p>
<p><span class="Bold">How should I use COSOPT PF?</span></p>
<p>Read the Instructions for Use at the end of this Patient Information leaflet for additional instructions about the right way to use COSOPT PF.
</p>
<ul class="Disc">
<li>Use COSOPT PF exactly as your doctor tells you.
</li>
<li><span class="Bold">Use 1 drop of COSOPT PF in your eye (or eyes) in the morning and 1 drop in the evening.</span></li>
<li>If you use other medicines in your eye, wait at least 5 minutes between using COSOPT PF and your other eye medicines.
</li>
<li>Use your COSOPT PF right away after opening. Each COSOPT PF single-use container is sterile and is to be used 1 time then thrown away.
</li>
<li>Do not save any COSOPT PF that may be left over after you use a single-use container. Using COSOPT PF that is not sterile may cause other eye problems.
</li>
</ul>
<p><span class="Bold">What are the possible side effects of COSOPT PF?</span></p>
<p><span class="Bold">COSOPT PF may cause serious side effects including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">severe breathing problems.</span> These breathing problems can happen in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Tell your doctor right away if you have breathing problems while taking COSOPT PF.
</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></span>. This can happen in people who already have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and in people who have never had <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> before.<br>Tell your doctor right away if you get any of these symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> while taking COSOPT PF:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>
</li>
<li>irregular heartbeat (<span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your ankles or feet
</li>
<li>sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>
</li>
</ul>
</li>
<li>
<span class="Bold">severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span> These <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> can happen the first time you use COSOPT PF or after you have been using COSOPT PF for a while and may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="Bold">Stop taking COSOPT PF and call your doctor right away or get emergency help if you get any of these symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>:</span><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, mouth, or tongue
</li>
<li>trouble breathing
</li>
<li><span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>
</li>
<li>severe <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>
</li>
<li>fast heartbeat or pounding in your chest (<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>)
</li>
<li><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>
</li>
</ul>
</li>
<li>
<span class="Bold">worsening <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>.</span> COSOPT PF can cause <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> to get worse in people who already have problems with <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> (<span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>).
</li>
<li>
<span class="Bold">kidney problems.</span> Your doctor may do tests to check your kidney function while you use COSOPT PF.
</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your eye (cornea)</span></li>
</ul>
<p>The most common side effects of COSOPT PF include:
</p>
<ul class="Disc">
<li>a bitter, sour, or unusual taste in your mouth after using COSOPT PF
</li>
<li>burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the eye
</li>
<li><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>
</li>
<li>painful, red, watery eyes with increased sensitivity (<span class="product-label-link" type="condition" conceptid="375265" conceptname="Punctate keratitis">superficial punctate keratitis</span>)
</li>
</ul>
<p>Tell your doctor if you have any new eye problems while using COSOPT PF including:
</p>
<ul class="Disc">
<li>an eye injury
</li>
<li>an <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infection</span>
</li>
<li>a sudden <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>
</li>
<li>eye surgery
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> of and around your eye (<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>)
</li>
<li>problems with your eyelids
</li>
</ul>
<p>Tell your doctor if you have any other side effects that bother you.
</p>
<p>These are not all the possible side effects of COSOPT PF. For more information, ask your doctor or pharmacist.
</p>
<p>Call your doctor about medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</p>
<p><span class="Bold">What should I do in case of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>?</span></p>
<p>If you swallow the contents of the container, contact your doctor immediately. Among other effects, you may feel light-headed, have <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, or feel your heart rate has slowed.
</p>
<p><span class="Bold">How should I store COSOPT PF?</span></p>
<ul class="Disc">
<li>Store COSOPT PF at room temperature between 68°F to 77°F (20°C to 25°C). Do not freeze.
</li>
<li>Keep the COSOPT PF single-use containers in their original foil pouch to protect from light.
</li>
<li>Write down the date you open the foil pouch in the space provided on the pouch.
</li>
<li>Throw away all unused COSOPT PF single-use containers 15 days after first opening the pouch.
</li>
</ul>
<p><span class="Bold">Keep COSOPT PF and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of COSOPT PF.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use COSOPT PF for a condition for which it was not prescribed. Do not give COSOPT PF to other people, even if they have the same symptoms you have. It may harm them. This Patient Information leaflet summarizes the most important information about COSOPT PF. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about COSOPT PF that is written for health professionals.
</p>
<p><span class="Bold">What are the ingredients in COSOPT PF?</span></p>
<p><span class="Bold">Active ingredients:</span> dorzolamide hydrochloride and timolol maleate
</p>
<p><span class="Bold">Inactive ingredients:</span> sodium citrate, hydroxyethyl cellulose, sodium hydroxide, mannitol, and water for injection.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Instructions for Use</span></p>
<p>Read these instructions before using your COSOPT PF and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.
</p>
<p><span class="Bold">Important:</span></p>
<ul class="Disc">
<li><span class="Bold">COSOPT PF is for the eye only. Do not swallow COSOPT PF.</span></li>
<li>COSOPT PF single-use containers are packaged in a foil pouch.
</li>
<li>Write down the date you open the foil pouch in the space provided on the pouch.
</li>
</ul>
<p><span class="Bold">Every time you use COSOPT PF:</span></p>
<p><span class="Bold">Step 1.</span> Wash your hands.
</p>
<p><span class="Bold">Step 2.</span> Take the strip of single-use containers from the pouch.
</p>
<p><span class="Bold">Step 3.</span> Pull off 1 single-use container from the strip.
</p>
<p><span class="Bold">Step 4.</span> Put the remaining strip of single-use containers back in the pouch and fold the edge to close the pouch.
</p>
<p><span class="Bold">Step 5.</span> Hold the single-use container upright. Make sure that the solution is in the bottom part of the single-use container <span class="Bold">(See <a href="#f03">Figure A</a>).</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Figure A
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e&amp;name=cos03-0000-03.jpg">
</div>
<p><span class="Bold">Step 6</span>. Open the single-use container by twisting off the tab <span class="Bold">(See <a href="#f04">Figure B</a>).</span></p>
<div class="Figure">
<a name="f04"></a><img alt="Figure B
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e&amp;name=cos03-0000-04.jpg">
</div>
<p><span class="Bold">Step 7.</span> Tilt your head backwards. If you are unable to tilt your head, lie down.
</p>
<p><span class="Bold">Step 8.</span> Place the tip of the single-use container close to your eye. Be careful not to touch your eye with the tip of the single-use container
</p>
<p><span class="Bold">(See <a href="#f05">Figure C</a>).</span></p>
<div class="Figure">
<a name="f05"></a><img alt="Figure C
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e&amp;name=cos03-0000-05.jpg">
</div>
<p><span class="Bold">Step 9.</span> Pull the lower eyelid downwards and look up.
</p>
<p><span class="Bold">Step 10.</span> Gently squeeze the container and let 1 drop of COSOPT PF <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> into the space between your lower eyelid and your eye. If a drop misses your eye, try again <span class="Bold">(See <a href="#f06">Figure D</a>).</span></p>
<div class="Figure">
<a name="f06"></a><img alt="Figure D
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e&amp;name=cos03-0000-06.jpg">
</div>
<p><span class="Bold">Step 11.</span> Blot any excess solution from the skin around the eye with a tissue.
</p>
<ul class="Disc">
<li>If your doctor has told you to use drops in both eyes, repeat steps 7 to 11 for your other eye.
</li>
<li>There is enough COSOPT PF in 1 single-use container for 1 or both of your eyes.
</li>
<li><span class="Bold">Throw away the opened single-use container with any remaining COSOPT PF right away.</span></li>
</ul>
<p><span class="Bold">This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.</span></p>
<p><span class="Bold">AKORN<br></span>Distributed by: Akorn, Inc.<br>Lake Forest, IL 60045
</p>
<p>The COSOPT trademark is owned by Merck Sharp &amp; Dohme Corp. and is used under license.
</p>
<p>PF00N Rev. 12/13
</p>
<p>AK60300
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s63"></a><a name="section-18"></a><p></p>
<p class="First">Principal Display Panel Text for Container Label:
</p>
<p>COSOPT<span class="Sup">®</span> PF 2% / 0.5%
</p>
<p>(dorzolamide HCl – timolol
</p>
<p>maleate ophthalmic solution)
</p>
<p>Rx only
</p>
<div class="Figure">
<a name="f07"></a><img alt="Principal Display Panel Text for Container Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e&amp;name=cos03-0000-07.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s64"></a><a name="section-19"></a><p></p>
<p class="First">Principal Display Panel Text for pouch Label:
</p>
<p>NDC 17478-604-01
</p>
<p>COSOPT<span class="Sup">®</span> PF
</p>
<p>(dorzolamide HCl – timolol maleate
</p>
<p>Ophthalmic solution) 2% / 0.5%
</p>
<p>For Topical Application in the Eye
</p>
<p>Sterile  Preservative-Free
</p>
<div class="Figure">
<a name="f08"></a><img alt="Principal Display Panel Text for pouch Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e&amp;name=cos03-0000-08.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s65"></a><a name="section-20"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>NDC 17478-604-90
</p>
<p>COSOPT<span class="Sup">®</span> PF
</p>
<p>(dorzolamide HCl – timolol maleate
</p>
<p>Ophthalmic solution) 2% / 0.5%
</p>
<p>For Topical Application in the Eye
</p>
<p>Sterile  Preservative-Free
</p>
<div class="Figure">
<a name="f09"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a8d4e2b5-c7bb-48fc-9314-7095cd77617e&amp;name=cos03-0000-09.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>COSOPT PF 		
					</strong><br><span class="contentTableReg">dorzolamide hydrochloride and timolol maleate solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-604</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Dorzolamide Hydrochloride</strong> (Dorzolamide) </td>
<td class="formItem">Dorzolamide</td>
<td class="formItem">20 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Timolol Maleate</strong> (Timolol Anhydrous) </td>
<td class="formItem">Timolol Anhydrous</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hydroxyethyl Cellulose (2000 MPA.S AT 1%)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Citrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-604-90</td>
<td class="formItem">12  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-604-01</td>
<td class="formItem">15  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.2 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:17478-604-30</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:17478-604-01</td>
<td class="formItem">15  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">0.2 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:17478-604-15</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:17478-604-00</td>
<td class="formItem">15  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">0.2 mL in 1 VIAL, SINGLE-USE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202667</td>
<td class="formItem">05/14/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Akorn, Inc.
							(062649876)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b6b1dacb-551a-44b2-92e2-86ede1c46dd7</div>
<div>Set id: a8d4e2b5-c7bb-48fc-9314-7095cd77617e</div>
<div>Version: 1</div>
<div>Effective Time: 20140514</div>
</div>
</div> <div class="DistributorName">Akorn, Inc.</div></p>
</body></html>
